Osteosarcomas produce an extracellular matrix (ECM), called tumor osteoid, which is also the microscopic hallmark of these tumors. It can be difficult to differentiate tumor osteoid from other formations of ECM in intra-and extraskeletal soft tissue tumors, so that problems in differential diagnosis arise. Conventional special stainings provide a means to increase the reliability of the differential diagnosis, but do not identify the type of tumor conclusively as they only reflect physiochemical features and do not identify the molecular components of the matrix. The key to the solution of this problem is the immunohistochemical use of antibodies against bone matrix components. Matrix-immunohistochemistry using polyclonal and monoclonal antibodies against COL-I-C-peptide, Osteopontin, Osteonectin, Osteocalcin, and Decorin have proved to be a useful tool for the differentiation of osteoid in a series of 20 osteosarcomas with different variants of osteoid formation. For the detection of undifferentiated tumors, however, this method has not proved useful, since the cytoplasmatic immunoreactivity is variable. Molecular methods appear to be a more promising tool. Since the expression of Osteocalcin is known to be the last step of the osteoblastic differentiation, we have established a method to detect osteocalcin mRNA by RT-PCR. First studies of our group on the identification of the osteoblastic differentiation at the molecular level have revealed that Osteocalcin mRNA can be detected both in osteosarcoma cells and in non-skeletal tumor cell lines. In order to provide a reliable means of molecular tumor characterisation, thorough comparative studies on fresh and paraffin material of larger tumor series are in progress.